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Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine
Tumor Society estimates that theUnited States hasmore than 150,000 gastroenteropancreaticNETpatients. About 10%ofmetastatic
NETs can be unknown primary, and due to their rarity, dedicated treatment algorithms and regimens are not defined. Combination
of capecitabine and temozolomide (CAPTEM) is one of the systemic treatments used in gastroenteropancreatic NETs.We explored
clinical activity of CAPTEM in NET of unknown primary.Methods. Retrospective review of NET of unknown primary managed at
the University of Kentucky over the past five years (2012–2016). Result. 56 patients with NET of unknown primary were identified;
12 patients were treated with CAPTEM. Median progression-free survival on CAPTEM in grade II and grade III NET of unknown
primary was 10.8 and 7 months, respectively. Six patients showed reduction in metastatic tumor volume at three-month CT scan.
Three patients had stable disease and three patients showed disease progression at the first surveillance scan. Common side-effects
were as follows: four patients developed grade II thrombocytopenia, three patients developed grade I lymphocytopenia, and two
patients developed hand foot syndrome (grades I and III). Six patients developed grade I fatigue. Conclusion. CAPTEM should be
considered for grades I and II NET of unknown primary, especially in the case of visceral crisis or bulky disease.
1. Introduction
Better diagnostics, recognition, and knowledge of neuroen-
docrine tumors (NETs) have led to consistent growth in
their incidence and prevalence. SEER data suggests a 6-fold
increase in the incidence from 1 per 100,000 patients in
1973 to almost 7 per 100,000 patients in 2012 [1]. Despite
rising burden of the disease, therapeutic options are limited.
Combination of capecitabine and temozolomide (CAPTEM)
is one of the chemotherapeutic options for progressive
metastatic gastroenteropancreatic neuroendocrine tumors.
Data regarding the use of CAPTEM in NETs of unknown
primary is lacking. NET of unknown primary accounts for
about 10–15% of all NETs [2]. Historically NETs of unknown
primary are thought to be relatively aggressive and confer a
poor prognosis [3]. We present our single center experience
of CAPTEM in this very rare cohort of disease.
2. Methods
Patients with neuroendocrine tumor of unknown primary
were identified from the Markey Cancer Center’s database
over a period of five years (2012–2016). IRB approval was
obtained for retrospective chart review prior to starting
the study. Neuroendocrine tumor of unknown primary was
defined by lack of visual evidence of primary tumor on CT
scan and or Octreoscan. Neuroendocrine tumors were histo-
pathologically graded based on 2010 WHO classification.
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Grade 1 was defined as Ki-67 < 2%, grade 2 had Ki-67
index between 2% and 20%, and grade 3 was defined as Ki-
67 index more than 20%. Patients treated with CAPTEM
regimen were analyzed for radiologic response in the first
scan, time to progression on treatment, and toxicity. We used
1500mg/m2 capecitabine and 200mg/m2 temozolomide for
treatment of our patients. Capecitabine was administered
continuously from days 1 to 14 daily in two divided doses (q
12 hours). Temozolomide was administered on days 10–14 in
two divided doses (q12 hours). Eastern cooperative oncology
group performance status criteria were utilized to assess the
fitness of patient. Grade 0was defined as fully active and being
able to perform all activities without restrictions. Grade 1 was
defined as restricted strenuous physical activity but able to
carry out light work. Grade 3 was defined as being able to
perform limited self-care. Grade 4 was completely disabled
and grade 5 was defined as deceased. We used common
terminology criteria for adverse events (CTCAE 4.03) to
define toxicity. We did not use RECIST criteria to assess
radiological response. Radiological response was categorized
into progressive disease, stable disease, partial response, and
complete response based on descriptive reading of radiologi-
cal report.
2.1. Patient Characteristics. A total of 56 patients with
neuroendocrine tumors were identified. Twelve of these
patients were treated with capecitabine and temozolomide.
The median age of the patients 12 patients was 62 and 6 of
them were women and 6 were men. Three patients had an
ECOG Performance Status (ECOG PS) of 0 and remaining 9
patients had an ECOG PS of 1. A specific Ki-67 was available
in two patients, the solitary grade 1 NET was 1%, and a grade
2 NET was 15%. The remaining patients were graded as I,
II, and III as per the current guidelines that classify grade
1 as a Ki-67 of less than 2%, grade 2 between 2 and 20%,
and grade 3 as more than 20%. One patient had a grade
1 NET, 7 with grade 2 NET, and 4 with grade 3 NET. Ten
patients were classified as well-differentiated NET and two
patients were poorly differentiated NET. Three patients had
received previous treatments; one of them a grade 2 NET
received carboplatin with etoposide and everolimus prior
to the use of CAPTEM, the second patient a grade 3 NET
received cisplatin with etoposide followed by carboplatin
with paclitaxcel, and a third patient with grade 3 NET
received carboplatin and etopside.The chromogranin A level
was available at the time of starting CAPTEM in 8 of the
12 patients and ranged from 3.8 to 1505 (median 221). The
most common sites of metastasis were to liver (10 patients),
peritoneum (4 patients), bone (2 patients), brain (1 patient),
and the heart (1 patients). Five patients received concomitant
somatostatin analogs at the time of treatment with CAPTEM.
Eight patients had an Octreoscan performed at the time of
start of CAPTEM and four of them demonstrated uptake.
3. Results
CAPTEM was used as front-line systemic therapy in 9
out of 12 patients. Median progression-free survival (PFS)
on CAPTEM in grade II and grade III NET of unknown
Table 1: Patient characteristics.
Characteristic Number
Total patients with NET 56
Total patients treated with CAPTEM 12
Median age 62 years
Male : female ratio 1 : 1
Mean duration of treatment before progression 10.8 months
CAPTEM used as front-line systemic therapy 9 patients
Median chromogranin A 221
Concomitant Somatostatin analogues use 5 patients
Grade I 1
Grade II 7
Grade III 4
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Figure 1: Kaplan-Meier curve depicting progression-free survival
while on CAPTEM.
primary was 10.8 and 7 months, respectively. Figure 1 shows
Kaplan-Meier curve for progression-free survival of NETs
of unknown primary on CAPTEM. The median number of
cycles received in the entire cohort was 6. The sole grade I
NETpatient was lost to follow-up after being on treatment for
at least 6 months. 6 patients showed reduction in metastatic
tumor volume at three-month CT scan. Three patients had
stable disease and 3 patients showed disease progression at
the first surveillance scan (Table 1). Response rate at three
months in grade 2 NET (complete response/partial response)
was 57% and response rate in grade 3 NET was 25%. Disease
control rate (complete response/partial response/stable dis-
ease) at three months in grade 2 NET was 100%.
Following were the rates of common side-effects: Four
patients developed grade II thrombocytopenia, three patients
developed grade I lymphocytopenia, two patients developed
hand and foot syndrome (one each, grades I and III), and six
patients developed grade I fatigue (Table 2).
4. Discussion
Neuroendocrine tumors are considered an orphan disease
due to low incidence, but despite this fact, the prevalence of
Journal of Oncology 3
Table 2: Rates of common side-effects.
Side-effect Grade Number
Thrombocytopenia II 4
Lymphocytopenia I 3
Hand and foot syndrome I 1
Hand and foot syndrome III 1
Fatigue I 6
neuroendocrine tumors is on the rise. The North American
Neuroendocrine Tumor Society estimates that there are
over 150,000 gastroenteropancreatic neuroendocrine tumor
patients in the United States alone. This imbalance between
incidence and prevalence is due to indolent history of disease
progression. Because of its orphan status, therapeutic clinical
trials are few and the treatment options for progressive
disease are limited.
CAPTEM is one of the suggested treatment regimens
for progressive well-differentiated neuroendocrine tumors.
Capecitabine is a prodrug that is converted from fluoropy-
rimidine to 5-fluorouracil upon oral intake. 5-Fluorouracil
has anticancer activity that induces damage to DNA by
inhibiting thymidylate synthase [4, 15]. Temozolomide is a
lipophilic methylator derived from dacarbazine—an alky-
lating agent used as a chemotherapy drug. The cytotoxicity
of temozolomide is a consequence of guanine methylation
which causes apoptosis of cancer cells [5, 16]. Several stud-
ies have researched various combinations of capecitabine
and temozolomide with other established chemotherapeutic
drugs, such as streptozocin as treatment for unresectable
NETs.Though streptozocin-based therapy is considered stan-
dard of care, the response rates for these combinations have
largely ranged from 6% to 42% and displayed considerable
toxicity [4, 15, 17], which restricted its use in clinical set-
tings. Capecitabine monotherapy has also been studied and
recorded to bewell tolerated in patients. It had a 9.68%overall
disease control rate, 36.5-month median overall survival,
and a 9.9-month median PFS (range: 4.4–36.7 months) [18].
Single agent temozolomide-based therapy has observed a
response rate (RR) of 34% for pancreatic neuroendocrine
tumors and 2% RR for carcinoid tumors [16].
The rationale for combining capecitabine and temo-
zolomide came from the hypothesis that the effects of
capecitabine would enhance NET cell sensitivity to the
lipophilic methylator, temozolomide [4, 15]. Simultaneous
administration of both drugs on day 1 had insufficient
results and substantial toxicity. A regimen of oral intake
of capecitabine preceding temozolomide by 9 days was
proposed for optimal synergy [15]. This was most likely
accredited to the role of O6-methylguanine DNA methyl-
transferase (MGMT)—a DNA repair enzyme. Capecitabine
causes depletion of the MGMT gene, which in turn allows
the cancer cells to be highly sensitive to temozolomide.
Based on the few studies involving CAPTEM, the dosage
for capecitabine ranges from 600mg/m2 to 1500mg/m2,
averaging at 750mg/m2. Temozolomide doses range from
150mg/m2 to 200mg/m2. Typically, capecitabine is adminis-
tered on days 1 to 14 and temozolomide on days 10 to 14 every
21 or 28 days.
There is very limited literature that observes the outcomes
of CAPTEM as treatment for well-differentiated neuroen-
docrine tumors. Table 3 summarizes the current data on
CAPTEM in NETs. A recent Phase II study evaluated the
efficacy of CAPTEM in NET patients and reported 97% clin-
ical benefit in their study cohorts, which included pancreatic
NET, gastrointestinal NET, pituitary gland, and medullary
thyroid neuroendocrine tumors. They reported an overall
relative risk of 43%, including 11% complete responses, and
54% stable disease rate [6]. Another recent study evaluated
the outcome of 65 NET patients treated with CAPTEM. It
is the largest study on CAPTEM to date and the data was
extracted from the abstract. The majority of study patients
(46/65) were pancreatic neuroendocrine tumors (PNETs)
and the RR was 47.7%, including 3.1% complete responses,
44.6% partial responses, and 41.5% stable disease. Median
PFS was recorded to be 16.1 months [7].
The results from the studies in Table 3 are encouraging
and confirm clinical antitumor activity and manageable toxi-
city. Although data from a Phase III randomized controlled
trial regarding use of CAPTEM is lacking, it is a widely
accepted treatment for progressive gastroenteropancreatic
NETcases that have failed FDAapproved front-line therapies.
Of note, most of the studies showed a better response rate
when CAPTEM was used as front-line therapy.
Current literature on CAPTEM mainly stems from pan-
creatic neuroendocrine tumor patients [8]. Evidence for the
high sensitivity of PNETs to CAPTEM has been attributed
to the lower expression of MGMT in PNETs than other
NET subtypes. Studies that have compared the outcomes
and efficacy of CAPTEM in patients with PNETs versus
non-PNETs do show significant overall response rates even
in non PNETs, although PNETs are noted to show a more
favorable response. Treatment on PNETs exhibited an objec-
tive response rate (ORR), disease control rate (DCR), and
PFS of 43–70%, 70–97%, and 12–18 months, respectively.
Comparatively, treatment on non-PNETs showed an ORR,
DCR, and PFS of 33–42%, 56–64%, and 10.5–22 months
[15]. Other studies comparing PNETs to non-PNETs found
no difference in PFS between the two cohorts, although the
data was not statistically significant [4, 9]. An important
factor which was noted to affect response rates was timing
of CAPTEM. This regimen was found to be less effective in
patients previously treated with other targeted therapies. A
recent study evaluating CAPTEM as first-line therapy versus
subsequent lines reported a median PFS of 15.9 months
versus 3.1 months, respectively [9]. CAPTEM’s effectiveness
with regard to Ki-67 and MGMT expression are currently
being researched in clinical studies. The literature shows an
exceptionally higher response to CAPTEM when Ki-67 >
5% (ORR = 64%) than when Ki-67 < 5% (ORR = 29%)
[19]. However, explicit conclusions cannot be made on the
predictive roles ofMGMTorKi-67 without further evidence-
based research.
Though various subtypes of NETs have been studied,
there is a significant lack of data on the effectiveness of
4 Journal of Oncology
Table 3: Outcomes and results of CAPTEM.
Primary site, % Pts (n) Prior treatment
CAP/TEM
dosage
(mg/m2)
Results
(%)
PFS
(months) Observed toxicities, %
Peixoto et al. [4]
Pancreatic, 48.3
Small bowel, 20.7
Lung, 10.3
Rectum, 6.9
Appendix, 3.4
Unknown, 10.3
29
(i) Octreotide
(ii) Local therapy
(iii) Chemotherapy
(iv) Targeted therapy
Cap: 750
Tem: 200 N/A 4.7 N/A
Fine et al. [5]
Pancreatic, 39
MEN1, 11
Carcinoids, 22.5
Gastrinoma, 11
Glucagonoma, 5.5
Insulinoma, 11
18
(i) Octreotide
(ii) Chemotherapy
(iii) Chemoembolization
Cap: 600
Tem: 150–200
CR: 6
PR: 56
SD: 22
14
Thrombocytopenia (grade 3 toxicity), 11
Hand-foot syndrome (grade 2), 5.5
Lymphopenia (grade 1/2), 50
Neutropenia (grade 1/2), 44
Fine et al. [6]
Pancreatic, 39
Atypical/typical
carcinoid, 42.8
Pituitary, 10.7
Thyroid gland, 7
28 (i) Octreotide Cap: 750Tem: 150–200
CR: 11
PR: 32
SD: 54
PD: 3
22
Lymphopenia (grade 3/4), 32
Hyperglycemia (grade 3/4), 15
Thrombocytopenia (grade 3/4), 3
Crespo et al. (abstract only) [7]
Pancreatic, 70.8 65 N/A N/A
CR: 3
PR: 45
SD: 42
16
Grade 3/4 toxicity, 13.8
Thrombocytopenia, 10.8
Neutropenia, 7.7
Strosberg et al. [8]
Pancreatic, 100 30 (i) Octreotide(ii) Local therapy
Cap: 750
Tem: 200
PR: 70
SD: 27
PD: 3
18
Grade 3/4 toxicity, 12
Hand-foot syndrome
Ramirez et al. [9]
Pancreatic, 52
Small bowel, 31
Lung, 10
Rectal, 7
29
(i) Cytoreduction
(ii) Targeted therapy
(iii) Radionuclide therapy
(iv) Chemotherapy
Cap: 750
Tem: 200
PR: 17
SD: 48
PD: 34
12
Thrombocytopenia grade 1 (3), grade 2 (3),
grade 3 (1)
Lymphocytopenia grade 1 (3), grade 2 (9),
grade 3 (3)
Neutropenia (grade 4), 3
Hand-foot syndrome grade 1 (6), grade 2 (3)
Spada et al. [10]
Pancreatic, 55
GI & unknown, 24
Lung, 21
58 (i) Octreotide(ii) Chemotherapy
Cap: 1,500
Tem: 150–200
PR: 22
SD: 52
PD: 23
13 Thrombocytopenia (grade 3/4)
Fine et al. [11]
Metastatic NETs 10 (i) Octreotide(ii) Chemotherapy
Cap: 750
Tem: 150–200
CR: 16
PR: 34
SD: 50
NA Hand-foot syndrome (grade 3), one case.
Saif et al. [12]
Pancreatic, 100 7
(i) Octreotide
(ii) Local therapy
(iii) Chemotherapy
Cap: 1,000
Tem: 200
PR: 43
SD: 28
PD: 29
12
Thrombocytopenia (grade 3), one case.
Fatigue (grade 3), one case
Neutropenia (grade 1/2)
Hand-foot syndrome (grade 1/2)
Abbasi et al. [13]
Pancreatic
Rectum
Colon
Stomach
21
(i) Octreotide
(ii) Chemotherapy
(iii) Local therapy
Cap: 600
Tem: 50–200
PR: 57
SD: 23
PD: 20
17 No grade 4 toxicity
Journal of Oncology 5
Table 3: Continued.
Primary site, % Pts (n) Prior treatment
CAP/TEM
dosage
(mg/m2)
Results
(%)
PFS
(months) Observed toxicities, %
Ramirez et al. [14]
Pancreatic, 50
Small bowel, 30
Lung, 13
Rectum, 7
30 N/A N/A
PR: 33
SD: 40
PD: 27
11 Cytopenia, 25Hand-foot syndrome, 35
N/A: not available, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, Cap: capecitabine, and Tem: temozolomide.
CAPTEM in NET of unknown primary. Only two studies
mentioned in Table 3 incorporatedNETof unknown primary
in their analysis. Peixoto et al. included 3 patients with
unknownprimary and reported PFS data (12months) on only
one of those three [4]. Spada et al. also included a group of
NET of unknown primary along with gastroenteropancreatic
subtype [20]. Our cohort is the largest NET of unknown
primary treated with CAPTEM. Our results suggest definite
clinical activity of CAPTEM in this rare cohort of NETs.
Moreover, the ability of CAPTEM to cytoreduce the tumor
with a relatively safe side-effect profile makes it a reasonable
choice of systemic therapy in progressive NET of unknown
primary.
Limitations. Because neuroendocrine tumors of unknown
primary are a rare disease, the study population was small.
In addition, as a retrospective study missing data and a
nonrandomized patient population were constraints in the
analysis. We did not use RECIST criteria for radiological
response assessments.
5. Conclusion
CAPTEM shows activity in NET of unknown primary. Cur-
rent FDA approved treatment options for grade I and grade II
GI NETs includes somatostatin analogs and everolimus, both
of which are cytostatic and of limited use in case of visceral
crisis or bulky disease where disease shrinkage is required.
CAPTEM should be considered for grades I and II NET of
unknown primary, especially in the case of visceral crisis or
bulky disease. While a randomized trial would be optimal
to confirm the benefit of CAPTEM in NET of unknown
primary, the rarity of these tumors precludes the feasibility
of a prospective trial.
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